TAK

TAKEDA PHARMACEUTICAL CO LTD TAK

NYSELarge CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #1,579 of 2,925

Why it scores 51Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$4.58T

Quarter to Mar 31

Net income

$107.93B

Quarter to Mar 31

Free cash flow

$856.39B

Quarter to Mar 31

Operating margin

7.5%

Quarter to Mar 31

Top Institutional Holders

as of Q2 2026
$1.75B total
Capital Research Global Investors
$309.34M+1.0%
FMR LLC
$153.88M+34.9%
MORGAN STANLEY
$112.13M+8.1%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$96.99M-5.8%
GOLDMAN SACHS GROUP INC
$82.15M-8.8%
Pacer Advisors, Inc.
$79.74M+6.6%
BRANDES INVESTMENT PARTNERS, LP
$72.77M+2.5%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$59.84M+19.8%
BlackRock, Inc.
$59.12M+16.1%
RENAISSANCE TECHNOLOGIES LLC
$41.17M-14.1%
Qube Research & Technologies Ltd
$35.39MNew
FIRST TRUST ADVISORS LP
$33.90M+7.3%
D. E. Shaw & Co., Inc.
$32.85M-21.3%
MANAGED ASSET PORTFOLIOS, LLC
$29.24M+1.4%
NORTHERN TRUST CORP
$27.90M-11.3%
VAN ECK ASSOCIATES CORP
$26.83M-25.9%
ENVESTNET ASSET MANAGEMENT INC
$25.62M+13.2%
AQR CAPITAL MANAGEMENT LLC
$24.46M+70.6%
Quantinno Capital Management LP
$22.48M+8.8%
WELLS FARGO & COMPANY/MN
$18.45M+1.3%
MILLENNIUM MANAGEMENT LLC
$16.84MNew
UBS Group AG
$14.61M-66.7%
Crossmark Global Holdings, Inc.
$12.56M+0.9%
JPMORGAN CHASE & CO
$11.90M+64.1%
STIFEL FINANCIAL CORP
$11.59M+15.0%
See all 382 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Operating Margin

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

TAK key financials by period

Reported revenue, net income and operating margin by fiscal year, from TAKEDA PHARMACEUTICAL CO LTD's annual filings on SEC EDGAR.

TAKEDA PHARMACEUTICAL CO LTD reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$4581.6B$107.9B7.5%
FY 2024$4263.8B$144.1B5.0%
FY 2023$4027.5B$317.0B12.2%
FY 2022$3569.0B$230.1B12.9%
FY 2021$3197.8B$376.0B15.9%
FY 2020$3291.2B$44.2B3.0%
Source: TAK filings on SEC EDGAR →

Companies similar to TAK

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

TAK insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in TAK

5 transactions in TAK reported by 2 members of Congress under the STOCK Act, most recent trade Aug 29, 2023. Reported transactions, not recommendations.

All Congress stock trades →

About TAKEDA PHARMACEUTICAL CO LTD (TAK): stock profile, AI score and financials

TAKEDA PHARMACEUTICAL CO LTD (TAK) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TAK at 51.0/100 on a composite quality score built from its SEC filings, placing it at rank #1,579 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), TAKEDA PHARMACEUTICAL CO LTD reports quarterly revenue of $4581.6B, net income of $107.9B, an operating margin of 7.5%. Top institutional holders of TAK by reported 13-F value include Capital Research Global Investors, FMR, MORGAN STANLEY, based on the most recent SEC filings. TAK trades on the NYSE exchange and files with the SEC under CIK 1395064. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TAK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TAKEDA PHARMACEUTICAL CO LTD directly from SEC EDGAR.

SEC EDGAR: CIK 1395064 →